Rapid Medical News
20 articles
Rapid Medical™ Announces Japanese Approval and Exclusive Partnership With Kaneka for TIGERTRIEVER-The World's Only Adjustable Thrombectomy Device
Rapid Medical's TIGERTRIEVER™ Delivers First-Pass Success in Challenging Ischemic Stroke Patients with ICAD
Rapid Medical™ Gains Approval in China for the World's Only Adjustable Thrombectomy Device
New Data Shows Advantages of Rapid Medical's COMANECI™ Embolization Assist Device
Rapid Medical Gains FDA Clearance for the Smallest & Only Adjustable Thrombectomy Device
Rapid Medical Marks First Procedures with Numen™ Coil from MicroPort Scientific
Rapid Medical Enrolls the First Patient in the DISTALS Stroke Trial-Offering Treatment to New Ischemic Stroke Patient Population
Rapid Medical Receives FDA Breakthrough Device Designation for Vasospasm Treatment
Rapid Medical to Initiate the First-Ever Trial to Expand Stroke Treatment to Distal Regions of the Brain-Offering Thrombectomy Treatment to New Patient Population
Israeli stroke treatment co Rapid Medical raises $50m
Rapid Medical, an Israeli neurovascular device developer, has completed a $50 million Series D financing round led by MicroPort. The investment will be used to support the companys fast commercial growth of its minimally invasive neurovascular devices worldwide. Rapid Medical recently received FDA clearance for its TIGERTRIEVER revascularization device for the treatment of ischemic stroke. The funding will be used to expand commercial operations in the US and Europe, create additional clinical evidence, advance product development, and obtain regulatory approvals in new strategic territories such as China. Chen Chen from CITIC private equity fund (CPE) will join Rapid Medicals board of directors as part of the financing round.
InvestmentExpand
Rapid Medical Receives FDA Clearance for the World's First Steerable Neurovascular Guidewire
Rapid Medical Receives CE Mark for TIGERTRIEVER™ XL
Rapid Medical has received CE Mark for TIGERTRIEVER XL, the newest addition to their portfolio of neurovascular devices. The device is designed to treat ischemic stroke and is the largest and longest stentriever available. The adjustable diameter of TIGERTRIEVER XL can conform to any vessel diameter up to 9mm. The company has successfully treated the first patients with the device. The addition of TIGERTRIEVER XL to their product lineup is expected to have a positive impact on the companys growth. Rapid Medical is focused on developing game-changing devices for neurovascular treatments.
Customers
Rapid Medical wins FDA nod for Comaneci embolization assist device
Rapid Medical has received FDA 510(k) clearance for its Comaneci device, a temporary coil embolization assist system. The device is the first and only one cleared by the FDA in its category. Comaneci is an adjustable, fully-visible aneurysm remodeling device that acts as a temporary bridge during the coiling process, reducing the risk of complications. It does not require vessel occlusion or long-term medication. The clearance is expected to contribute to the companys growth. Rapid Medical recently received a $20 million investment in a Series C funding round, with MicroPort Scientific participating.
Investment
Rapid Medical Raises $20 Million in New Funding to Support Clinical and Commercialization of First-in-class Stroke Treatment Products
Rapid Medical has completed an oversubscribed Series C financing of $20 million led by JAM Capital Partners and MicroPort. The funding will be used to complete the TIGER U.S. IDE study and support the companys commercial growth in stroke treatment and prevention products. Rapid Medical also entered into a partnership with MicroPort for marketing rights in China. The financing round demonstrates the potential impact of Rapid Medicals products and technology for stroke patients.
InvestmentPartners
Rapid Medical Receives CE Mark Approval for TIGERTRIEVER 13
Rapid Medical has received CE Mark approval for the TIGERTRIEVER 13, a next-generation neurovascular device designed to treat ischemic stroke patients. The device is the newest addition to the Tigertriever family and is 83% smaller than any other device on the market. It is designed to recanalize intracranial vessels of 1mm - 2.5mm, which account for up to 30% of ischemic stroke patients. The TIGERTRIEVER 13 will extend endovascular therapy to patients with medium vessel occlusions. Rapid Medical plans to launch the device in Europe during Q3 2018.
Customers
Rapid Medical: First Patient Enrolled to the TIGER Pivotal Clinical Study
Rapid Medical has enrolled the first patients in the TIGER study, a multi-center study of the performance of their novel thrombectomy device for the acute treatment of ischemic stroke. The study aims to support the companys 510(k) submission to the U.S. FDA for clearance to market the device in the U.S. The TIGERTRIEVER has already been used to treat over a thousand patients in Europe and is the subject of a post-marketing registry in several European countries. The device is a controllable stentriever designed to address the limitations of current devices and improve patient outcomes. Rapid Medical is a company developing game-changing devices for endovascular treatments.
Customers
Rapid Medical (Israel): First Patient Enrolled To The TIGERTRIEVER Acute Ischemic Stroke Registry - Israël Science Info
Rapid Medical, a company focused on the development of neurovascular interventional devices, announced the enrollment of the first patient in the TIGERTRIEVR registry in Switzerland. The TIGERTRIEVER is a stentriever used to treat acute ischemic stroke. The registry is designed to demonstrate the benefits of the TIGERTRIEVER in real-life usage. Rapid Medical also plans to initiate a clinical study for FDA clearance. The company recently closed a $9M financing round to advance the commercialization of its products.
CustomersInvestment
Rapid Medical raises $9m in Series B for neurovascular devices
Rapid Medical, a neurovascular device maker, has closed a $9 million Series B round of financing to support its stroke treatment and prevention devices. The funding will be used to pursue FDA regulatory clearance and advance European commercialization of its Tigertriever revascularization device and Comaneci adjustable remodeling mesh. The company plans to initiate a clinical trial for the Tigertriever next year. The financing round was led by BRM Group and Shanghai-Israel Investment Fund, with participation from Winnovation and Gefen Capital. As part of the financing, Rapid Medical has added three new members to its board of directors. The company aims to become a leader in the neurovascular field.
InvestmentExpand
Rapid Medical reaches 500 successful aneurysm treatments with Comaneci - NeuroNews International
Rapid Medicals Comaneci adjustable remodelling mesh has successfully treated over 500 aneurysms worldwide. The device, which integrates the advantages of existing adjuvant devices, provides temporary assistance for coil embolisation of intracranial aneurysms. It allows for constant flow during the procedure and can be adjusted to fit the dimensions of parent vessels and the aneurysm neck. Rapid Medical plans to launch the Comaneci in additional regions in the coming months.
Customers
Rapid Medical Announces First Stroke Patient Treated With TIGERTRIEVER
Rapid Medical announced the treatment of the first patient with its TIGERTRIEVER revascularization device. The device uses Rapid Medicals proprietary technology to fit the dimensions of blocked blood vessels that cause acute ischemic stroke. The device received positive feedback from physicians and is expected to become the leading device for stroke intervention. Rapid Medical plans to launch the TIGERTRIEVER in Europe during Q2 2016.
Customers
